Avalyn Pharma Inc. AVLN
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -13.09%
- 1 year
- -13.09%
- Open
- 25.71
- Prev close
- 25.71
- Mkt cap
- 1.14B
- Vol
- 343.50K
- Avg vol
- 281.23K
- EPS
- -2.47
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 24.85
- High
- 26.17
- Forward P/E
- -9.93
- Beta
- 0.00
- Short ratio
- 7.21
- Inst. own
- 104.07%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 11, 2026
- 50-d avg
- 30.39
- 200-d avg
- 30.03
- 1y target
- 61.80
5D chart
Signals (105)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 29, 3:10 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:10 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:30 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:25 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:30 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:20 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:15 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:10 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 12:35 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 12:20 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:15 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:10 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:05 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:05 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 12:05 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 11:40 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:35 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:35 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:00 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:00 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:55 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:25 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:20 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:15 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:45 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:40 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:45 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:35 PM | 3 days ago |
| RSI: Oversold | Oct 28, 2:10 PM | 3 days ago |
| RSI: Oversold | Oct 28, 1:50 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:40 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 1:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:50 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 12:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 12:45 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:40 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 12:10 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 11:50 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:45 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 11:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:20 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:45 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:00 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:55 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:45 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 4 days ago |
| RSI: Overbought | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:55 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:45 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:30 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:25 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:45 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:40 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:25 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:15 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:45 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 11:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:40 AM | 5 days ago |
| RSI: Oversold | Oct 27, 11:20 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:55 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 10:55 AM | 5 days ago |
| RSI: Oversold | Oct 27, 10:55 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:25 AM | 5 days ago |
| RSI: Oversold | Oct 27, 10:15 AM | 5 days ago |
| RSI: Oversold | Oct 27, 9:50 AM | 5 days ago |
| RSI: Oversold | Oct 27, 9:30 AM | 5 days ago |
| RSI: Oversold | Oct 26, 3:40 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:05 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:55 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:55 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:20 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:15 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:05 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:55 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 12:45 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 5 days ago |
| SMA: Bullish | Oct 26, 11:10 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
News
1 month ago benzinga.com
This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts initiated coverage: VYLR Outperform/$85, LBRX Buy/$68, ELVN Overweight/$70, SAIL Sector Weight, and AVLN Outperform/$60.
-
1 month ago benzinga.com
Raymond James Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $60
Raymond James analyst Tiago Fauth initiates coverage on Avalyn Pharma (NASDAQ:AVLN) with a Outperform rating and announces Price Target of $60.
1 month ago defenseworld.net
Avalyn Pharma Inc. (NASDAQ:AVLN) Stock Now Rated “Moderate Buy” by Wall Street Analysts
Avalyn Pharma Inc. (NASDAQ: AVLN - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six research firms that are presently covering the company, MarketBeat reports.…
-
1 month ago benzinga.com
Avalyn Pharma Says Respiratory Research Publishes Detailed Results From Two Phase 1 Clinical Trials Of AP02 In Healthy Volunteers And Patients With IPF, Validating Inhaled Antifibrotic Approach
Results validate Avalyn’s approach of delivering established antifibrotic medicines directly to the lungs to maximize local exposure while limiting systemic exposure and improving…
1 month ago globenewswire.com
Avalyn Publishes Phase 1 Data Highlighting AP02's Lung-Targeted Delivery and Encouraging Safety Profile
Results validate Avalyn's approach of delivering established antifibrotic medicines directly to the lungs to maximize local exposure while limiting systemic exposure and improving tolerability
1 month ago globenewswire.com
Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors
BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the…
1 month ago seekingalpha.com
Avalyn Pharma Inc. (AVLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Avalyn Pharma Inc. (AVLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
-
1 month ago benzinga.com
Avalyn Pharma Reports New Data Showing Predicted Aerosol Distribution Of AP01 And Survey Data Highlighting Patient Perspectives On Participation In Clinical Studies For Idiopathic Pulmonary Fibrosis
In silico modeling predicts robust AP01 distribution in healthy and fibrotic lungs, even in severe diseasePatient survey findings suggest that clear communication, transparent discussions of…
1 month ago globenewswire.com
Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious,…
1 month ago globenewswire.com
Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis
In silico modeling predicts robust AP01 distribution in healthy and fibrotic lungs, even in severe disease Patient survey findings suggest that clear communication, transparent discussions of…
2 months ago globenewswire.com
Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026
Presentations describe integration of patient perspective into clinical trial design and data modeling AP01 distribution in the lungs Presentations describe integration of patient perspective into…
-
2 months ago benzinga.com
Morgan Stanley Maintains Overweight on Avalyn Pharma, Raises Price Target to $57
Morgan Stanley analyst Judah Frommer maintains Avalyn Pharma (NASDAQ:AVLN) with a Overweight and raises the price target from $53 to $57.
-
2 months ago benzinga.com
Avalyn Pharma Q2 EPS $(0.65) Misses $(0.53) Estimate
Avalyn Pharma (NASDAQ:AVLN) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.53) by 22.64 percent.
2 months ago globenewswire.com
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027 Two abstracts accepted for presentation at the European Respiratory…
4 months ago globenewswire.com
Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis
Company expects to report topline 12-month clinical results in the second half of 2027 Company expects to report topline 12-month clinical results in the second half of 2027
4 months ago marketbeat.com
Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead
Avalyn Pharma NASDAQ: AVLN executives outlined the company's inhaled pulmonary fibrosis strategy at the Jefferies Global Healthcare Conference, emphasizing its recent IPO, ongoing mid-stage studies…
5 months ago globenewswire.com
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
On track to complete enrollment of MIST Phase 2b trial of AP01 in progressive pulmonary fibrosis (PPF) in mid-2026, with newly presented long term open-label extension clinical data that support…
5 months ago globenewswire.com
Avalyn to Participate in the Jefferies Global Healthcare Conference
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious,…
-
5 months ago benzinga.com
Evercore ISI Group Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $51
Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Avalyn Pharma (NASDAQ:AVLN) with a Outperform rating and announces Price Target of $51.
5 months ago benzinga.com
This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analysts have mixed views on AVLN stock.
-
5 months ago benzinga.com
Guggenheim Initiates Coverage On Avalyn Pharma with Buy Rating, Announces Price Target of $80
Guggenheim analyst Seamus Fernandez initiates coverage on Avalyn Pharma (NASDAQ:AVLN) with a Buy rating and announces Price Target of $80.
-
5 months ago benzinga.com
Morgan Stanley Initiates Coverage On Avalyn Pharma with Overweight Rating, Announces Price Target of $53
Morgan Stanley analyst Judah Frommer initiates coverage on Avalyn Pharma (NASDAQ:AVLN) with a Overweight rating and announces Price Target of $53.
-
5 months ago benzinga.com
Avalyn Pharma To Present Updated Findings From ATLAS Open-Label Extension Trial Highlighting Long-Term Tolerability Profile Of AP01 For Treatment Of Pulmonary Fibrosis, At EULAR 2026
Avalyn Pharma Inc. (NASDAQ:AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced an…
5 months ago globenewswire.com
Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious,…
-
5 months ago benzinga.com
Avalyn To Present Findings From Usability Study For eFlow Nebulizer System At American Thoracic Society 2026 International Conference May 15-20
The company's poster presentations are listed below and will be presented in the following session: Thematic Poster Session B39 – Breath and Burden: Diffuse Lung Diseases and Daily Life, Monday, May…
5 months ago globenewswire.com
Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious,…
6 months ago seekingalpha.com
U.S. IPO Weekly Recap: Biotech, Early-Stage Mining, And Bill Ackman Close Out The April IPO Market
Four IPOs priced this past week, led by three sizable biotechs. They were joined by 11 blank check listings. Two IPOs are currently scheduled for the week ahead, though some smaller names may join…
6 months ago globenewswire.com
Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
BOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious,…
6 months ago globenewswire.com
Avalyn Announces Pricing of Upsized Initial Public Offering
BOSTON, April 29, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (“Avalyn”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of…
6 months ago seekingalpha.com
U.S. IPO Weekly Recap: Nuclear Tech, Critical Materials, And More In A 4 IPO Week
Four IPOs priced this past week, featuring nuclear tech, critical materials, real estate, and convenience stores. One IPO is currently scheduled for the week ahead, joined by Bill Ackman's Pershing…
6 months ago seekingalpha.com
U.S. IPO Weekly Recap: Pipeline Swells With Sizable IPO Filings As Metals Royalty Direct Lists
One IPO priced this past week, joined by two SPACs, and twelve deals joined the pipeline. Three sizable IPOs are currently scheduled in the week ahead, and some smaller issuers may join the calendar…